The global COVID-19 vaccine packaging and delivery devices market size was valued at USD 962.0 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.4% from 2022 to 2028. COVID-19 vaccines are packed in multidose glass vials like many other pharmaceutical liquid formulations. The distribution will require suitable packaging to avoid wastage. The speeding rollouts, expanding production capacity, and a significant number of vaccines in the late stages of clinical approvals are the factors expected to primarily contribute to the growth of the market for COVID-19 vaccine packaging and delivery devices. Till April 2021, more than 50.0% of the U.S. population aged 65 years has been fully vaccinated.
The manufacturers are ramping up their production capacity to meet the mounting global demand. The increased production capacity is expected to boost the demand for packaging materials. For instance, In February 2021, AstraZeneca partnered with IDT Biologika to build a new manufacturing site in Germany. IDT biological, is a German contract research manufacturer, also involved in the production and filling of glass vials. The speed at which the virus is mutating itself into a more infectious strain is anticipated to boost the immunization demand, propelling the market growth.
Increasing investment in R&D to develop packaging materials of superior performance in terms of material strength and chemical inertness is expected to fuel the growth of the market for COVID-19 vaccine packaging and delivery devices. For instance, Corning Incorporated develops an innovative glass vial called “Valor”. It is a unique glass vial having benefits over conventional borosilicate vials. The benefits of the Valor glass vial include delamination resistance, breakage resistance, and reduced particulate generation.
According to the Our World in Data report, till March 4, 2021, around 270 million doses of COVID-19 vaccines have been administered globally. The U.S. contributes to around 30% of the total dose administered. The national government in several countries is vaccinating people at a faster pace, which is expected to propel the demand. For instance, BD received an order from the U.S. government to supply 50 million needles and syringes by end of 2020 to support vaccination campaigns.
The syringes segment dominated the COVID-19 vaccine packaging and delivery devices market and held the largest revenue share of 61.5% in 2021. The segment is further divided into empty and prefilled syringes. The average volume of a single COVID-19 dose is estimated to be 0.5 ml, thereby 1.0 ml of sterile empty syringes are preferred. In addition, some vaccine candidates require to be reconstituted with diluent solutions before administration, in such cases an additional empty syringe (2/3 ml) is required. Pfizer developed a vaccine that needs to be reconstituted with saline; thereby, the pace of the roll-out program is expected to significantly influence the segment.
The prefilled syringes segment is anticipated to witness the fastest growth during the forecast period. To vaccinate the 7.0 billion world population in a shorter time is a tedious process with the established logistic network. The presence of distribution constraints associated with current COVID-19 packaging systems is expected to increase the preference for prefilled syringes. For instance, In December 2020, BD invested USD 1.2 billion to expand its manufacturing capacity of pre-filled syringes.
Vials can be classified as plastic and glass vials. As vaccine components interact with the polymers of the plastic vial it is not frequently used for the storage of biological liquids. Whereas Type 1 borosilicate glass vials are used for COVID-19 vaccine storage. However, there is a significant gap between the demand and supply of glass vials that are anticipated to boost the demand for treated plastic vials. For instance, SiO2 Materials Science, a company developed plastic vials coated with a nanolayer of organosilica, making them shatterproof and mechanically strong. This can be a potential substitute for glass vials moving forward.
North America dominated the COVID-19 vaccine packaging and delivery devices market and held the largest revenue share of 39.3% in 2021. According to the CDC data, till 5 March 2021, 15.9 % of the total U.S. population has received a single dose of the COVID-19 vaccine, while 8.1% of the population has been fully vaccinated. Besides, the presence of numerous government initiatives such as Operation Wrap Speed (OWS), Biomedical Advanced Research and Development Authority (BARDA), and Defense Production Act (DPA) is expected to fasten the production and distribution of COVID-19 vaccines driving the demand for packaging material.
In Europe, the COVID-19 vaccine packaging and delivery devices market held the second-largest revenue share in 2021. The region has robust vaccine production and packaging facilities. The growing concern in EU member states to keep the vaccination rate at par with countries such as U.K. and U.S. is one of the key factors expected to boost the growth of the market for COVID-19 vaccine packaging and delivery devices. For instance, in February 2021, BioNTech, a German vaccine procedure starts production of the COVID-19 vaccine at its new production site in Germany to boost the supply to the EU.
In the Asia Pacific, the market for COVID-19 vaccine packaging and delivery devices is expected to experience the fastest growth rate over the forecast period. China, India, and Korea are among the notable markets for COVID-19 vaccine packaging and delivery device manufacturers. As tight vial supplies are threatening the delivery of vaccines globally, the Asian vial manufacturers are promptly expanding their production capacity to make larger revenue. The China Vaccine Industry Association (CVIA) predicts the annual production of glass vials to reach 8.0 billion this year.
The key companies are observed to enter into long agreements with national governments and vaccine developers. For instance, in July 2020, BD entered into an agreement with the U.S. government to supply an additional 140 million injection devices, bringing the order total to 190 Million from BD itself. At the same time, the Canadian government bumped in its 75 Million injection device order.
The major market players are observed to adopt strategies such as market expansion, product differentiation, mergers, collaboration, and capacity expansion to be order winners in the highly competitive environment. For instance, in December 2020, Schott Kaisha, an Indian-based subsidiary of Schott AG, invested around USD 17 Million to expand its vial manufacturing capacity by 300 million to prepare for the potential surge in demand for vials and syringes. Some of the prominent players in the COVID-19 vaccine packaging and delivery devices market include.
BD
B. Braun Melsungen AG
Hindustan Syringes & Medical Devices Ltd.
Terumo
NIPRO Medical Corporation
SCHOTT AG
Gerresheimer AG
Cardinal Health
Report Attribute |
Details |
Market size value in 2022 |
USD 2.6 billion |
Revenue forecast in 2028 |
USD 3.6 billion |
Growth Rate |
CAGR of 5.4% from 2022 to 2028 |
Base year for estimation |
2021 |
Historical data |
2020 |
Forecast period |
2022 - 2028 |
Quantitative units |
Revenue in USD million and CAGR from 2022 to 2028 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; Japan; China; Thailand; South Korea; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
BD; B. Braun Melsungen AG; Hindustan Syringes & Medical Devices Ltd; Terumo; NIPRO Medical Corporation; SCHOTT AG; Gerresheimer AG; Cardinal Health |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2020 to 2028. For the purpose of this study, Grand View Research has segmented the global COVID-19 vaccine packaging and delivery devices market on the basis of product and region:
Product Outlook (Revenue, USD Million, 2020 - 2028)
Vials
Glass
Plastic
Syringes
Empty
Prefilled
Regional Outlook (Revenue, USD Million, 2020 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
China
Japan
India
Thailand
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global COVID19 vaccine packaging & delivery devices market size was estimated at USD 962.0 million in 2021 and is expected to reach USD 2.6 billion in 2022.
b. The global COVID19 vaccine packaging & delivery devices market is expected to grow at a compound annual growth rate of 5.4% from 2022 to 2028 to reach USD 3.6 billion by 2028.
b. The syringes segment dominated the global COVID-19 vaccine packaging & delivery devices market and held the largest revenue share of 61.5% in 2021.
b. North America dominated the COVID19 vaccine packaging & delivery devices market with a share of 39.3% in 2021. This is attributable to the domicile presence of key vaccine suppliers coupled with growing public awareness to get vaccinated.
b. Some key players operating in the COVID19 vaccine packaging & delivery devices market include BD, B. Braun Melsungen AG, and NIPRO Medical Corporation Hindustan Syringes & Medical Devices Ltd, Terumo, Gerresheimer AG, SCHOTT AG, and Cardinal Health.
b. Key factors that are driving the COVID-19 vaccine packaging & delivery devices market growth include increasing funding & investment in COVID19 vaccine research, growing vaccine production capacity, rising demand for vaccines especially in APAC countries, and increasing public trust in approved vaccines.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.